<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02291029</url>
  </required_header>
  <id_info>
    <org_study_id>CCFZ533X2203</org_study_id>
    <nct_id>NCT02291029</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CFZ533 in Patients With Primary Sjögren's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety,tolerability and preliminary therapeutic efficacy of
      multiple doses of intravenous infusion of CFZ533 monoclonal antibody in patients with primary
      Sjögren's syndrome(pSS)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2014</start_date>
  <completion_date type="Anticipated">August 27, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 29, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The changes in an EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) after 12 weeks treatment will be analysed and compared between the active treatment and placebo groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EULAR Sjögren's Syndrome Patient Reported Intensity (ESSPRI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>To assess the changes of ESSPRI between baseline and Week 13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician global assessment of the patient's overall disease activity (VAS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>To assess the changes of physician global assessment of the patient's overall disease activity (VAS) between baseline and Week 13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's global assessment of their disease activity (VAS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>To assess the changes of patient's global assessment of their disease activity (VAS) beween baseline and Week 13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form (36) Health Survey (SF-36)</measure>
    <time_frame>12 weeks</time_frame>
    <description>To assess the changes of SF-36 between baseline and Week 13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multidimensional Fatigue Inventory (MFI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>To assess the changes of MFI between baseline and Week 13</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Primary Sjögren's Syndrome</condition>
  <arm_group>
    <arm_group_label>CFZ533 active- Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple doses of CFZ533 intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CFZ533 placebo- Cohort 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>multiple doses of placebo intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CFZ533 active - Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple doses of CFZ533 s.c. injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CFZ533 placebo - Cohort 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>multiple doses of placebo s.c. injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CFZ533 Treatment Arm 1 - Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple doses of CFZ533 s.c. injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CFZ533 Treatment Arm 2 - Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of CFZ533 i.v. infusion and multiple doses of CFZ533 s.c. injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CFZ533 active - Cohort 1</intervention_name>
    <description>multiple doses of CFZ533 s.c. injection</description>
    <arm_group_label>CFZ533 active - Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CFZ533 placebo- Cohort 1</intervention_name>
    <description>multiple doses of placebo s.c. injection</description>
    <arm_group_label>CFZ533 placebo - Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CFZ533 active - Cohort 2</intervention_name>
    <description>multiple doses of CFZ533 intravenous infusion</description>
    <arm_group_label>CFZ533 active- Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CFZ533 placebo - Cohort 2</intervention_name>
    <description>multiple doses of placebo intravenous infusion</description>
    <arm_group_label>CFZ533 placebo- Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CFZ533 active -Cohort 3</intervention_name>
    <description>multiple doses of CFZ533 s.c. injection</description>
    <arm_group_label>CFZ533 Treatment Arm 1 - Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CFZ533 active - Cohort 3</intervention_name>
    <description>Single dose of CFZ533 i.v. infusion and multiple doses of CFZ533 s.c. injection</description>
    <arm_group_label>CFZ533 Treatment Arm 2 - Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of primary Sjögren's syndrome

          -  ESSDAI score ≥ 6

        Exclusion Criteria:

          -  Secondary Sjögren's syndrome

          -  Receiving cyclosphosphamide, corticosteroid bolus with dose over 1 mg/kg, rituximab,
             belimunab, other immunosuppressives.

          -  At significant risk for thromboembolic event

          -  Clinically significant systemic infection

          -  Significant elevated risk for infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edgbaston</city>
        <state>Birmingham</state>
        <zip>B15 2WB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>EC14 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>WC1E 6HX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE2 4HH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2014</study_first_submitted>
  <study_first_submitted_qc>November 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2014</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sjögren's syndrome, CFZ533, ESSDAI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

